Please login to the form below
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Cost-effectiveness league table (healthcare economics)
The league table comprises a list of healthcare interventions in ascending order (from low to high) of their incremental cost-effectiveness ratio (ICER). The ICER is frequently expressed as cost per quality adjusted life year (QALY) gained. If the goal of the healthcare system is to generate as many QALYs as possible, then a cost per QALY league table represents a prioritised list of interventions, from high priority (low cost per QALY) to low priority (high cost per QALY).
See also:
Cost effective (healthcare economics)
Cost effectiveness analysis (healthcare economics)
Quality of life (QOL)
Quality-adjusted life year (QALY)
Related terms
Competitors, Primary care, Discounted cash flow (DCF), Foundation Trust (FT), General practitioner (GP), Adherence, Leader pricing, Cost–benefit analysis, Health Maintenance Organisation (HMO), PEEST, Internal communications, Competitor analysis, European Association of Communications Agencies (EACA), Return on investment (ROI)/Return on capital employed (ROCE), NHS Evidence,
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
